Adapt Or Fail: The Urgency Of Pandemic Preparedness For Sterile Injectable Manufacturing

By Vincent Villegas, Sr. Director of Government Affairs and Strategic Initiatives

In 2020, JHS began building a more robust response infrastructure by expanding our manufacturing flexibility and produce sterile injectables in multiple vial and batch sizes. Our ongoing site expansion doubles our manufacturing capacity and increases our cold storage space for temperature-sensitive vaccines and medications. Our new lines are equipped with full isolator technology and three additional compounding suites. Isolator technology ensures the excellent level of quality and safety our partners need while scaling up batch sizes.

Our expansion also includes large state-of-the-art lyophilizers and additional operational space like loading docks, temperature-controlled storage, a high-speed packaging line, and environmental monitoring. Once we complete the final piece of our Spokane site expansion in 2026, JHS will be able to better assist in a public health emergency with the ability to make 60 million vials and service over 300 million patients in a single year.